A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolumab.